Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EWTX
SellHot AirEdgewise Therapeutics, Inc. · Healthcare · United States · $4.6B · Avg Vol: $53M/d
COMPANY DESCRIPTION
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapies for serious rare muscle disorders. The company's competitive moat lies in its novel scientific approach to muscle stabilization and protection, targeting conditions like Duchenne and Becker muscular dystrophy. Edgewise aims to provide orally bioavailable treatments that address significant unmet medical needs, potentially altering the course of these debilitating diseases.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | 139.6M | 42.7M | — |
| EPS | -1.14 | -0.31 | -1.57 | -0.42 | -1.63 | — | -1.85 | -2.09 | -1.56 | — |
| Shares | — | 63.3M | 70.5M | 94.8M | 106.2M | +68.0% | 108.6M | — | — | — |
| Debt | — | 4.4M | 5.4M | 4.7M | 4.0M | -3.3% | 3.6M | — | — | — |
| Equity | — | 346.7M | 318.8M | 459.2M | 522.3M | 14.6% | — | — | — | — |
| Op CF | — | -52.6M | -91.9M | -109.0M | -143.8M | — | -158.4M | — | — | — |
| Inv CF | — | -70.6M | 102.9M | -184.7M | -32.8M | — | — | — | — | — |
| Fin CF | — | 129.6M | 53.2M | 249.3M | 196.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EWTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc.(you) | $4.6B | 28 | Sell |
| RLAY | Relay Therapeutics, Inc. | $4.1B | 28 | Sell |
| LEGN | Legend Biotech Corporation | $3.9B | 30 | Sell |
| ORKA | Oruka Therapeutics, Inc. | $6.0B | 27 | Sell |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | 30 | Sell |
| MBX | MBX Biosciences, Inc. | $3.0B | 28 | Sell |
| MANE | Veradermics, Incorporated | $4.1B | 22 | Sell |
| DFTX | Definium Therapeutics, Inc. | $5.5B | 22 | Sell |
| PTCT | PTC Therapeutics, Inc. | $5.8B | 32 | Sell |
| DNTH | Dianthus Therapeutics, Inc. | $5.9B | 23 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%